Detail of "382180-17-8"

Reference

Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia

All Rights Reserved. Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia. Einsiedel, H. Graf; Kawan, L.Chemicals with cas numbers 149647-78-9 and 382180-17-8 also play role.; Eckert, C.; Witt, O.; Fichtner, I.; Henze, G.; Seeger, K. (Department of Pediatric Oncology/Hematology, Charite Universitaetsmedizin Berlin, Berlin, Germany). Leukemia, 20(8), 1435-1436 (English) 2006 Nature Publishing Group. CODEN: LEUKED. ISSN: 0887-6924. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The therapeutic potential of three hydroxamic acid-HDACI and of one short-chain fatty acid-HDACI and of one short-chain fatty-acid (VPA) in three B-cell precursor in vitro and in two non-obese diabetes/severe combined immunodeficiency mouse models of childhood ALL in vivo was detd. Data clearly demonstrate the principal efficacy of the HDAC1 Vorinostat and VPA in BCP-ALL of childhood, two substances already successfully used in clin. oncol. Thus, the next step toward a future use of HDAC1 in childhood ALL is justified, which will encompass comprehensive combination testing in vitro and in vivo of Vorinostat and VPA with established cytostatistics and also new, less toxic therapeutics to search for potential additive or synergistic interactions. Identifying such synergistic combinations will be an important step toward the development of effective, non-toxic therapies for children with relapsed ALL. .